Isofol Medical Past Earnings Performance
Past criteria checks 0/6
Isofol Medical has been growing earnings at an average annual rate of 22.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 20% per year.
Key information
22.3%
Earnings growth rate
53.8%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | -20.0% |
Return on equity | -43.1% |
Net Margin | n/a |
Next Earnings Update | 19 Feb 2025 |
Recent past performance updates
Recent updates
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow
Jul 12An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10Revenue & Expenses Breakdown
How Isofol Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -39 | 6 | 0 |
30 Jun 24 | 0 | -35 | 5 | 0 |
31 Mar 24 | 0 | -35 | 6 | 0 |
31 Dec 23 | 1 | -37 | 7 | 0 |
30 Sep 23 | 3 | -54 | 19 | 0 |
30 Jun 23 | 5 | -80 | 26 | 0 |
31 Mar 23 | 9 | -120 | 30 | 0 |
31 Dec 22 | 13 | -160 | 35 | 0 |
30 Sep 22 | 16 | -196 | 32 | 0 |
30 Jun 22 | 18 | -214 | 31 | 0 |
31 Mar 22 | 21 | -209 | 30 | 0 |
31 Dec 21 | 22 | -200 | 28 | 0 |
30 Sep 21 | 36 | -194 | 27 | 0 |
30 Jun 21 | 50 | -173 | 24 | 0 |
31 Mar 21 | 42 | -176 | 23 | 0 |
31 Dec 20 | 37 | -189 | 23 | 0 |
30 Sep 20 | 18 | -192 | 22 | 0 |
30 Jun 20 | 0 | -204 | -32 | 0 |
31 Mar 20 | 0 | -191 | -1 | 0 |
31 Dec 19 | 0 | -162 | 24 | 0 |
30 Sep 19 | 0 | -133 | 45 | 0 |
30 Jun 19 | 0 | -108 | 111 | 0 |
31 Mar 19 | 0 | -90 | 96 | 0 |
31 Dec 18 | 0 | -83 | 89 | 0 |
30 Sep 18 | 0 | -80 | 127 | 0 |
30 Jun 18 | 0 | -82 | 113 | 0 |
31 Mar 18 | 0 | -79 | 97 | 0 |
31 Dec 17 | 0 | -72 | 73 | 0 |
30 Sep 17 | 0 | -77 | 15 | 0 |
30 Jun 17 | 0 | -66 | 13 | 0 |
31 Mar 17 | 0 | -63 | 9 | 0 |
31 Dec 16 | 1 | -65 | 9 | 0 |
31 Dec 15 | 0 | -41 | 7 | 0 |
Quality Earnings: ISOFOL is currently unprofitable.
Growing Profit Margin: ISOFOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISOFOL is unprofitable, but has reduced losses over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare ISOFOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISOFOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: ISOFOL has a negative Return on Equity (-43.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 05:43 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Isofol Medical AB (publ) is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ulrik Trattner | Carnegie Investment Bank AB |
Ole-Andreas Krohn | DNB Markets |
David Martinsson | DNB Markets |